Loading...
XNASENTA
Market cap111mUSD
Jan 17, Last price  
5.25USD
1D
8.25%
1Q
-58.43%
Jan 2017
-84.33%
IPO
-68.77%
Name

Enanta Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:ENTA chart
P/E
—
P/S
1.65
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
0.18%
Rev. gr., 5y
-19.91%
Revenues
68m
-14.61%
22,763,00041,882,00041,706,00032,053,00047,741,000160,880,00088,268,000102,814,000206,625,000205,197,000122,473,00097,074,00086,160,00079,204,00067,635,000
Net income
-116m
L-13.28%
7,904,00023,310,00021,399,0009,627,00034,438,00078,992,00021,666,00017,710,00071,956,00046,383,000-36,168,000-78,996,000-121,755,000-133,816,000-116,045,000
CFO
-79m
L-23.64%
-10,175,00024,019,00022,623,00010,653,00020,179,00076,673,00035,809,00052,653,00029,220,00071,418,0007,088,000-69,996,000-84,782,000-103,154,000-78,764,000
Earnings
Feb 05, 2025

Profile

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
URL
https://www.enanta.com/
IPO date
Mar 21, 2013
Employees
160
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑092015‑09
Income
Revenues
67,635
-14.61%
79,204
-8.07%
86,160
-11.24%
Cost of revenue
189,326
216,411
212,977
Unusual Expense (Income)
NOPBT
(121,691)
(137,207)
(126,817)
NOPBT Margin
Operating Taxes
(1,743)
2,821
(433)
Tax Rate
NOPAT
(119,948)
(140,028)
(126,384)
Net income
(116,045)
-13.28%
(133,816)
9.91%
(121,755)
54.13%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,208
20,033
BB yield
-0.94%
-1.87%
Debt
Debt current
3,048
5,275
2,891
Long-term debt
109,410
47,751
47,635
Deferred revenue
(5,180)
Other long-term liabilities
136,360
161,515
1,877
Net debt
(135,728)
(316,884)
(227,991)
Cash flow
Cash from operating activities
(78,764)
(103,154)
(84,782)
CAPEX
(17,948)
(9,058)
(2,125)
Cash from investing activities
58,235
(53,578)
54,897
Cash from financing activities
(27,626)
198,126
20,033
FCF
(158,581)
(109,448)
(137,973)
Balance
Cash
248,186
369,910
249,232
Long term investments
29,285
Excess cash
244,804
365,950
274,209
Stockholders' equity
(322,526)
(207,958)
(75,272)
Invested Capital
644,691
612,721
418,566
ROIC
ROCE
EV
Common stock shares outstanding
21,157
20,969
20,603
Price
10.36
-7.25%
11.17
-78.47%
51.87
-8.70%
Market cap
219,187
-6.42%
234,224
-78.08%
1,068,678
-6.74%
EV
83,459
(82,660)
842,110
EBITDA
(119,355)
(134,836)
(123,844)
EV/EBITDA
0.61
Interest
10,940
5,148
1,573
Interest/NOPBT